To select the above DE lncRNAs for validation, it was taken in consideration one of the major characteristics of lncRNA, that is, high heterogeneous expression across the same tumor and even the same cell line. Long noncoding RNA’s expression is tightly regulated by a wild range of cellular responses and, due to the markedly lower transcriptional levels of lncRNAs, the expression variability inside the same group of patients is expected. Taking this aspects in consideration, from the top 25 positively DE lncRNAs and from the top 20 negatively DE lncRNAs, it were selected for validation those lncRNAs with low adjusted p-values to avoid this variability, especially in the comparison BRAFWT × BRAFV600E tumor, which is the focus of this research. As another desirable characteristic, most lncRNAs selected, presented at least in one group (normal thyroid, PTC, BRAFWT or BRAFV600E) a median expression greater than 1 RPKM (reads per kilo base per million mapped reads). Added to that, it was given preference for those lncRNAs without isoforms (seen that many lncRNAs have annotation errors) and that present at least 2 exons, which are more stable and would allow the PCR primers to be located in different exons.